GLP-1 receptor agonists could hold promise for opioid use disorder treatment
Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...
Medscape4d
The Glucagonostatic and Insulinotropic Effects of Glucagon-like Peptide 1 Contribute Equally to its Glucose-lowering Action
while the inhibition of α-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions ...
GlobalData on MSN1d
Zealand Pharma steadfastly upholds amylin-based obesity drug strategy
Zealand’s CEO Adam Steensberg said that the company is “exactly where it wants to be” in terms of its partnering and ...
Pharmaceutical Technology on MSN2d
GLP-1RAs and opioid use disorder: a new frontier in addiction treatment
While medications such as methadone, buprenorphine, and naltrexone are FDA-approved for treating opioid use disorder, they ...
Monthly Prescribing Reference2d
Treating Alcohol Use Disorder: GLP-1s Emerge as a Promising New Therapy
They lower blood sugar levels without significantly increasing the risk of hypoglycemia, suppress glucagon secretion ... 21 Most research on GLP-1 agonists as a potential therapy for AUD focuses ...
News Medical on MSN1d
Understanding the impact of weight loss medications on female reproductive health
In recent months, the efficacy of contraception for people taking weight loss medications has been questioned, as several women claim to have gotten pregnant despite using oral contraceptives.
Hosted on MSN4d
Why You're Not Losing Weight on Ozempic? 5 Possible Reasons
Ozempic. Wegovy and other GLP-1 medications have been hailed as groundbreaking treatments for individuals struggling with ...
Daily6d
Retinal examination be done at each visit: CDSCO Panel tells Alkem Lab on Semaglutide Injection Phase III CT study
At the recent SEC meeting for Endocrinology and Metabolism held on 13th January 2025, the expert panel reviewed the ...